News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
769,304 Results
Type
Article (63584)
Company Profile (446)
Press Release (705274)
Section
Business (221782)
Career Advice (3001)
Deals (38346)
Drug Delivery (113)
Drug Development (88177)
Employer Resources (180)
FDA (17726)
Job Trends (16386)
News (378878)
Policy (38175)
Tag
Academia (2928)
Alliances (54403)
Alzheimer's disease (1322)
Approvals (17621)
Artificial intelligence (132)
Bankruptcy (383)
Best Places to Work (12195)
Biotechnology (312)
Breast cancer (115)
Cancer (980)
Cardiovascular disease (91)
Career advice (2524)
Cell therapy (225)
Clinical research (69414)
Collaboration (351)
Compensation (174)
COVID-19 (2782)
Data (881)
Diabetes (148)
Diagnostics (6550)
Drug pricing (101)
Earnings (88686)
Employer resources (158)
Events (119188)
Executive appointments (255)
FDA (18188)
Funding (307)
Gene therapy (169)
GLP-1 (668)
Government (4877)
Healthcare (20255)
Infectious disease (2865)
Inflammatory bowel disease (115)
Interviews (551)
IPO (17148)
Job creations (4520)
Job search strategy (2110)
Layoffs (475)
Legal (9580)
Lung cancer (171)
Manufacturing (173)
Medical device (14128)
Medtech (14133)
Mergers & acquisitions (21194)
Metabolic disorders (424)
Neuroscience (1589)
NextGen Class of 2024 (7275)
Non-profit (4927)
Northern California (1234)
Obesity (251)
Opinion (237)
Patents (102)
People (62035)
Pharmaceutical (88)
Phase I (21399)
Phase II (30223)
Phase III (22797)
Pipeline (212)
Postmarket research (3286)
Preclinical (9374)
Radiopharmaceuticals (255)
Rare diseases (202)
Real estate (6815)
Regulatory (25040)
Research institute (2610)
Resumes & cover letters (483)
Southern California (1112)
Startups (4019)
United States (12304)
Vaccines (634)
Weight loss (208)
Date
Today (181)
Last 7 days (844)
Last 30 days (2993)
Last 365 days (37966)
2024 (32232)
2023 (42251)
2022 (53610)
2021 (58292)
2020 (57109)
2019 (50391)
2018 (38240)
2017 (35905)
2016 (36403)
2015 (42174)
2014 (36585)
2013 (31821)
2012 (33929)
2011 (34488)
2010 (33122)
Location
Africa (1013)
Arizona (210)
Asia (44782)
Australia (7515)
California (2854)
Canada (1186)
China (220)
Colorado (124)
Connecticut (131)
Europe (100302)
Florida (404)
Georgia (104)
Illinois (356)
Indiana (192)
Kansas (98)
Maryland (551)
Massachusetts (2333)
Michigan (152)
Minnesota (269)
New Jersey (858)
New York (863)
North Carolina (764)
Northern California (1234)
Ohio (130)
Pennsylvania (755)
South America (1413)
Southern California (1112)
Texas (403)
Washington State (335)
769,304 Results for "dr reddy s laboratories inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech (NASDAQ: ALVO) and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab).
May 21, 2024
·
14 min read
Dr. Reddy’s Laboratories launches Versavo® (bevacizumab) in the UK
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® in the United Kingdom.
March 19, 2024
·
5 min read
Business
Dr. Reddy’s Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
Dr. Reddy’s Laboratories Ltd., announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council.
May 28, 2024
·
5 min read
Business
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech and Dr. Reddy’s Laboratories today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab).
May 21, 2024
·
14 min read
Dr. Reddy’s Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Dr. Reddy’s Laboratories Ltd. today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).
May 3, 2024
·
3 min read
Business
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
May 7, 2024
·
21 min read
Business
Pharmazz Inc. and Dr. Reddy’s Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company developing and commercializing drug products to treat critically ill patients, announced that it has entered into a license agreement with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a global pharmaceutical company, to commercialize a first-in-class innovative drug Centhaquine in India.
March 22, 2024
·
5 min read
News
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
October 14, 2024
·
4 min read
Business
Dr. Reddy’s Q3 & 9M FY24 Financial Results
Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
January 31, 2024
·
18 min read
Business
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Dr. Reddy’s Laboratories SA and Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”), today announced that they have entered into a development and license agreement (the “Agreement”) for the development and commercialization of COYA 302.
December 6, 2023
·
14 min read
1 of 76,931
Next
